Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Xalatan approved in E.U. as first-line therapy for lowering IOP in glaucoma patients

April 24, 2002

ISTA to proceed with Vitrase NDA filing

April 12, 2002

Third phase III trial under way for INS-365 Ophthalmic in dry eye

April 9, 2002

Antiangiogenic effects demonstrated for CA4P in mouse model of proliferative retinopathy

April 4, 2002

Sucampo licenses development and marketing rights to eye drop formulation of tacrolimus

April 2, 2002

ISTA reports preliminary phase III results for Vitrase

March 28, 2002

ISTA updates clinical progress of Vitrase

March 19, 2002

Inhibition of iNOS provides neuroprotection in glaucoma

March 11, 2002

Functional and morphological effects of Epitalon in rat model of retinitis pigmentosa

March 11, 2002

Russian research yields polypeptide complex with efficacy in exudative AMD

March 11, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.